Loading stock data…
DERM
$5.19+0.04 (+0.78%)
Market ClosedLast close May 1
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Journey Medical Corporation in the Healthcare sector is trading at $5.19. The stock is currently near its 52-week low of $4.31, remaining 29.6% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why DERM maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.19
Potential Upside
5%
Whystock Fair Value$5.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$13.25+155.3%
Range$11.00 – $16.00
Fundamentals
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$167.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.89%
Volume
Today's trading volume
148,630
Recent News
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks
Journey Medical's fair value target has been adjusted to $13.25 from $13.50, putting a fresh spotlight on how analysts are framing the story around the stock. Some bullish voices see the updated target as a sign that current pricing does not fully capture the company’s recent execution, while more cautious views point out that the target still leans on consistent revenue momentum and margin discipline. As you read on, you will see how these differing opinions shape the evolving analyst...
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Journey Medical (DERM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Journey Medical Corporation Q4 2025 Earnings Call Summary
Moby summary of Journey Medical Corporation's Q4 2025 earnings call
Journey Medical Corp (DERM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Journey Medical Corp (DERM) reports a 10% revenue increase and positive adjusted EBITDA, while navigating competitive pressures and reimbursement challenges.
Journey Medical Q4 Earnings Call Highlights
Journey Medical (NASDAQ:DERM) executives highlighted a “milestone” 2025 marked by the commercial launch of EMROSI, an internally developed oral treatment for the inflammatory lesions of rosacea, and pointed to improved profitability metrics as the product ramps. On the company’s full-year 2025 resu